Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Basilea Pharmaceutica AG
BSLNCurrent price
40.7 CHF
-0.3 CHF (-0.73%)
Last closed
41 CHF
Company
www.basilea.com
ISIN
CH0011432447
Sector
Healthcare
Industry
Biotechnology
Exchange
SIX Swiss Exchange
Capitalization
515 646 449 CHF
Yield for 12 month
+13.85 %
1Y
3Y
5Y
10Y
15Y
BSLN
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland. Address: Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
72.46 CHFP/E ratio
–Dividend Yield
–Current Year
+158 908 611 CHF
Last Year
+148 959 812 CHF
Current Quarter
+76 909 896 CHF
Last Quarter
+73 317 079 CHF
Current Year
+131 897 957 CHF
Last Year
+121 940 085 CHF
Current Quarter
+24 775 727 CHF
Last Quarter
+56 383 252 CHF
Key Figures BSLN
1 year
3 years
5 years
10 years
EBITDA
-5 641 753 CHF
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-2.05 %
PEG Ratio
–
Return On Equity TTM
-4.1 %
Wall Street Target Price
72.46 CHF
Revenue TTM
150 226 975 CHF
Book Value
1.4 CHF
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-10.1 %
Dividend Yield
–
Gross Profit TTM
49 757 103 CHF
Earnings per share
-0.071 CHF
Diluted Eps TTM
-0.071 CHF
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
-33.2 %
Profit Margin
-0.44 %
Dividend Analytics BSLN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BSLN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
11.04.2013
Forward Annual Dividend Yield
–
Last Split Factor
1039:1029
Payout Ratio
–
Last Split Date
13.03.2007
Dividend Date
–
Stock Valuation BSLN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
10.0604
Enterprise Value Revenue
3.7645
Price Sales TTM
3.4324
Enterprise Value EBITDA
24.279
Price Book MRQ
30.4707
Financials BSLN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BSLN
For 52 weeks
32.26 CHF
48.34 CHF
50 Day MA
45.28 CHF
Shares Short Prior Month
–
200 Day MA
41.38 CHF
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart